AUTO3 (CD19/22 CAR T cells not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.”In the company’s words, NCT03289455 on ClinicalTrials.gov
- Tested for
- B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia
- Main trialPhase 1/2
- “The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 in paediatric or young adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia.”In the company’s words, NCT03289455 on ClinicalTrials.gov
Other drugs for B-cell Acute Lymphoblastic Leukemia
- TisagenlecleucelNovartis · Phase 3
- Human immunoglobulin GCSL Behring · Phase 3
- MK-1045Merck & Co. · Phase 2/3
- YK012Excyte Biopharma Ltd · Phase 1/2
- Autologous BCMA/CD19 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/CD38 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 18 May 2020 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026